Innovation Pharmaceuticals Inc (IPIX)

[Brinjal]

Could it be that the lack of enthusiasm for CERC's announcement stems from the fact that their candidate is a monoclonal antibody, and therefore harder to manufacture in bulk and is also more expensive?

https://www.nature.com/articles/d41586-020-02965-3

Moreover, they are up against Regeneron's candidate, and Regeneron is considered to be a leader in their Covid therapy.

Brilacidin falls in a different class of drugs, and does not have a direct competitor...yet.